Erste Asset Management GmbH Grows Stake in Biohaven Ltd. $BHVN

Erste Asset Management GmbH boosted its position in shares of Biohaven Ltd. (NYSE:BHVN) by 643.1% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 693,300 shares of the company’s stock after purchasing an additional 600,000 shares during the quarter. Erste Asset Management GmbH’s holdings in Biohaven were worth $7,851,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of the company. Vanguard Group Inc. increased its holdings in Biohaven by 52.9% during the 4th quarter. Vanguard Group Inc. now owns 4,395,946 shares of the company’s stock worth $49,630,000 after purchasing an additional 1,520,756 shares during the period. Geode Capital Management LLC increased its holdings in Biohaven by 16.1% during the 4th quarter. Geode Capital Management LLC now owns 2,392,277 shares of the company’s stock worth $27,014,000 after purchasing an additional 332,069 shares during the period. BNP Paribas Financial Markets increased its holdings in Biohaven by 148.2% during the 4th quarter. BNP Paribas Financial Markets now owns 2,093,816 shares of the company’s stock worth $23,639,000 after purchasing an additional 1,250,252 shares during the period. Holocene Advisors LP lifted its holdings in Biohaven by 19.1% during the second quarter. Holocene Advisors LP now owns 1,495,641 shares of the company’s stock worth $21,103,000 after buying an additional 239,889 shares during the period. Finally, Capital Research Global Investors lifted its holdings in Biohaven by 31.8% during the fourth quarter. Capital Research Global Investors now owns 1,332,792 shares of the company’s stock worth $15,047,000 after buying an additional 321,262 shares during the period. 88.78% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts have weighed in on BHVN shares. Raymond James Financial restated a “strong-buy” rating on shares of Biohaven in a report on Wednesday, May 27th. Wall Street Zen cut Biohaven from a “sell” rating to a “strong sell” rating in a research note on Sunday, April 26th. Leerink Partners restated an “outperform” rating and set a $15.00 price objective on shares of Biohaven in a research note on Tuesday, March 3rd. Royal Bank Of Canada decreased their price objective on Biohaven from $23.00 to $22.00 and set an “outperform” rating for the company in a research note on Tuesday, May 5th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Biohaven in a research note on Tuesday, June 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $22.27.

Biohaven Trading Up 3.0%

Shares of NYSE:BHVN opened at $11.12 on Tuesday. The business’s 50-day moving average is $9.79 and its 200 day moving average is $10.46. Biohaven Ltd. has a 1 year low of $7.48 and a 1 year high of $18.57. The firm has a market capitalization of $1.67 billion, a P/E ratio of -1.96 and a beta of 1.35. The company has a debt-to-equity ratio of 1.87, a current ratio of 7.41 and a quick ratio of 7.41.

Biohaven (NYSE:BHVN) last announced its earnings results on Monday, May 4th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.86) by ($0.02). On average, research analysts predict that Biohaven Ltd. will post -3.03 earnings per share for the current fiscal year.

Biohaven Profile

Biohaven Ltd. (NYSE BHVN) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapies for neurological and neurovascular diseases. Founded in 2013 as a spin-out from Yale University, Biohaven focuses on addressing high-unmet medical needs through innovative small-molecule and peptide-based platforms. The company is headquartered in New Haven, Connecticut, and maintains research activities across the United States, with collaborative ties in Europe and Asia via strategic partnerships.

The company’s most advanced program centers on calcitonin gene-related peptide (CGRP) receptor antagonists for the acute and preventive treatment of migraine.